Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson's disease

Basal Ganglia

Volumn 2, Issue 4 SUPPL., 2012, Pages

  Jost, Wolfgang H ^a   Friede, Michael ^b   Schnitker, Jörg ^c  

^a DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^b Lundbeck GmbH   (Germany)

^c Institut für Angewandte Statistik   (Germany)

Author keywords

Meta analysis; Parkinson's disease; Rasagiline; Selegiline

Indexed keywords

PLACEBO; RASAGILINE; SELEGILINE;

AGITATION; ANXIETY; ARTICLE; BACKACHE; COMBINATION CHEMOTHERAPY; CONFUSION; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FAINTNESS; HALLUCINATION; HUMAN; INSOMNIA; MENTAL PERFORMANCE; META ANALYSIS; MONOTHERAPY; MOTOR PERFORMANCE; NAUSEA; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SCHWAB AND ENGLAND SCALE; SCORING SYSTEM; SENSITIVITY ANALYSIS; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; VOMITING; XEROSTOMIA;

EID: 84872383940     PISSN: 22105336     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.baga.2012.05.006     Document Type: Article

References (48)

1. Diener HC, Putzki N. Leitlinien der Deutschen Gesellschaft für Neurologie. 5. überarbeitete Auflage. Stuttgart, New York: Thieme;2012.
2. DeLong MR, Juncos JL. Chapter 366. Parkinson's disease and other extrapyramidal movement disorders. In: Fauci AS, Braunwald E, Kasper DL et al., editors. Hrsg. Harrison's Online McGraw-Hill: accessed Oct 24th 2010.
3. Brunton L., Parker K., Blumentahl D., et al. Hrsg. Goodman and Gilman's manual of pharmacology and therapeutics 2007, McGraw-Hill, New York, [p. 343].
4. Leegwater-Kim J., Bortan E. The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging 2010, 5:149-156.
5. Olanow C.W., Rascol O., Hauser R., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009, 361:1268-1278.
6. Bar-Am O.B., Amit T., Youdim M.B. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 2004, 355:169-172.
7. Glenny A.M., Altman D.G., Song F., Sakarovitch C., et al. Indirect comparisons of competing interventions. Health Technol Assess 2005, 9:1-134. [iii-iv].
8. Schöttker B, Lühmann D, Boulkhemair D, Raspe H. Indirekte Vergleiche von Therapieverfahren. Schriftenreihe Health Technology Assessment (HTA) in der Bundesrepublik Deutschland Bd 88. Köln 2009: Deutsches Institut für Medizinische Dokumentation und Information (DIMDI). doi: 10.3205/hta000071L.
9. Song F., Altman D.G., Glenny A.M., Deeks J.J. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003, 326(7387):472. 10.1136/bmj.326.7387.472.
10. Higgins JPT, Green S, Eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. Section 6: Searching for studies. The Cochrane Collaboration: 2009. http://www.cochrane-handbook.org.
11. Higgins JPT, Green S, Eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. Section 16.6.2: Indirect comparisons. The Cochrane Collaboration: 2009. http://www.cochrane-handbook.org.
12. Higgins JPT, Green S, Eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. Section 9: Analysing data and undertaking meta-analyses. The Cochrane Collaboration: 2009. http://www.cochrane-handbook.org.
13. Macleod A.D., Counsell C.E., Ives N., Stowe R. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev 2005, 20(3). CD004898.
14. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
15. Verhagen A.P., de Vet H.C., de Bie R.A., et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998, 51:1235-1241.
16. Fahn S., Elton R. Members of the UPDRS Development Committee. Recent Developments in Parkinson's Disease, Vol 2 1987, Macmillan Health Care, Florham Park, NJ, 3-163, 293-304. S. Fahn, C.D. Marsden, D.B. Calne, M. Goldstein (Eds.).
17. Siderowf A., McDermott M., Kieburtz K., et al. Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial. Mov Disord 2002, 17:758-763.
18. Yahr M.D., Duvoisin R.C., Schear M.J., et al. Treatment of parkinsonism with levodopa. Arch Neurol 1969, 21:343-354.
19. Schwab R.S., England A.C. Projection technique for evaluating surgery in Parkinson's disease. Third symposium of parkinson's disease 1969, E & S Livingston, Edinburgh. F.J. Gillingham, I.M.L. Donaldson (Eds.).
20. Rabey J.M., Sagi I., Huberman M., et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000, 23:324-330.
21. Parkinson Study Group A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002, 59:1937-1943.
22. Rascol O., Brooks D.J., Melamed E., et al. LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005, 365:947-954.
23. Stern M.B., Marek K.L., Friedman J., et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord 2004, 19:916-923.
24. Parkinson Study Group A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005, 62:241-248.
25. Tetrud J.W., Langston J.W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989, 245:519-522.
26. Shults C.W. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Parkinson Study Group. Acta Neurol Scand Suppl 1993, 146:36-42.
27. Myllylä V.V., Sotaniemi K.A., Hakulinen P., et al. Selegiline as the primary treatment of Parkinson's disease - a long-term double-blind study. Acta Neurol Scand 1997, 95:211-218.
28. Allain H., Pollak P., Neukirch H.C. Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial. Mov Disord 1993, 8(Suppl 1):S36-40.
29. Nappi G., Martignoni E., Horowski R., et al. Lisuride plus selegiline in the treatment of early Parkinson's disease. Acta Neurol Scand 1991, 83:407-410.
30. Olanow C.W., Hauser R.A., Gauger L., et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995, 38:771-777.
31. Larsen J.P., Boas J., Erdal J.E. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group. Eur J Neurol 1999, 6:539-547.
32. Pålhagen S., Heinonen E.H., Hägglund J., et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 1998, 51:520-525.
33. Wu-wie Zhao., Xiao-jun He., Zhi-feng Zhang., et al. Influence of selegiline on dopaminergic neurons in patients with early Parkinson disease. Chinese J Clin Rehab 2005, 9:190-192.
34. Golbe L.I. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease. Neurology 1989, 39:1109-1111.
35. Lees A.J. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 1995, 311:1602-1607.
36. Dalrymple-Alford J.C., Jamieson C.F., Donaldson I.M. Effects of selegiline (deprenyl) on cognition in early Parkinson's disease. Clin Neuropharmacol 1995, 18:348-359.
37. Kirollos C., Charlett A., Bowes S.G., et al. Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinsonism. Eur J Clin Pharmacol 1996, 50:7-18.
38. Przuntek H., Conrad B., Dichgans J., et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol 1999, 6:141-150.
39. Takahashi M., Yuasa R., Imai T., et al. Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial. Intern Med 1994, 33:517-524.
40. Ives NJ, Stowe RL, Marro J, et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ. 2004;329(7466):593. Epub 2004 Aug 13. doi: 10.1136/bmj.38184.606169.AE.
41. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Memantin bei Alzheimer Demenz: Ergebnisse der unpublizierten Studien IE2101 und MEM-MD-22 sowie unpublizierter Responderanalysen. IQWiG-Berichte Nr. 74, 2010. http://www.iqwig.de/download/Arbeitspapier_zu_Memantin_bei_Alzheimer_Demenz.pdf.
42. Borenstein M, Hedges L, Rothstein H. Meta-analysis. Fixed effects vs. Random effects. 2007. http://www.meta-analysis.com.
43. Senn S. Statistical issues in drug development 1997, John Wiley & Sons, Chichester.
44. Senn S. The many modes of meta. Drug Inf J 2000, 34:535-549.
45. Senn S. Trying to be precise about vagueness. Stat Med 2007, 26:1417-1430.
46. Schrag A., Sampaio C., Counsell N., et al. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord 2006, 21:1200-1207.
47. Knudsen-Gerber D.S. Selegiline and rasagiline: twins or distant cousins?. Guidel Cosnult Pharm 2011, 26:48-51.
48. Callaghan R.C., Cunningham J.K., Sajeev G., et al. Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. Mov Disord 2010, 25:2333-2339.